Caplin Point Laboratories Ltd

NSE
CAPLIPOINT •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Caplin Point Laboratories Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High in past week
24.7
TTM PE Ratio
Below industry Median
26.4
Price to Book Ratio
Above industry Median
6.3
Dividend yield 1yr %
Below industry Median
0.3
TTM PEG Ratio
PEG TTM is slightly more than 1
1.1
RSI
RSI is mid-range
57.1
MFI
MFI Overbought
75

Caplin Point Laboratories Ltd Key Financials

*All values are in ₹ Cr.

Caplin Point Laboratories Ltd shareholding Pattern

Promoter
70.6%
Foreign Institutions
2.8%
Mutual Funds
0.4%
Domestic Institutions
0.4%
Public
26.1%

Caplin Point Laboratories Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
12
Bearish Moving Averages
4
5Day EMA
1,541.60
10Day EMA
1,525.90
12Day EMA
1,518.90
20Day EMA
1,495.20
26Day EMA
1,479.70
50Day EMA
1,419.80
100Day EMA
1,306.60
200Day EMA
1,147.40
Delivery & Volume
Resistance & Support
1,530.50
Pivot
Resistance
First Resistance
1,546
Second Resistance
1,570.50
Third Resistance
1,586
Support
First Support
1,506
Second support
1,490.50
Third Support
1,466
Relative Strength Index
57.07
Money Flow Index
75.04
MACD
39.20
MACD Signal
34.17
Average True Range
56.98
Average Directional Index
33.20
Rate of Change (21)
1.16
Rate of Change (125)
47.80

Caplin Point Laboratories Ltd Company background

Founded in: 1990
Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16th, 1990. The Company is a fully integrated Pharma Company and is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market. Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India. It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations over 36 therapeutic sections.Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries. In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well. It manufactures products one among which is for injectables approved interalia by EUGMP, INVIMA, Colombia, Anvisa, Brazil and US FDA. Besides these, it has extended to regulated markets like USA (plans for Canada, Australia, China and Brazil).The company came out with a public issue in Nov.94 and expanded its production capacity by setting up a new unit to manufacture its range of products, at Pondicherry. The company has retained its SSI status even after the expansion and thus will be out of the purview of the DPCO. During 199394, Triwin (a partnership firm) was merged with Caplin Point. The company entered into a technical agreement with American Remedies and Concord Laboratories, US, for specific products, with a 30% buyback arrangement. It also imports biotechnological products to market them in India.The company has established a trading branch in Nairobi, Kenya, to sell its products in East Africa. It has also established a warehouse in Miami, US, by entering into a marketing tieup with Lockett Medical Corporation, US.During the year 2015, the Company has invested a sum of Rs 89.10 Lakhs in Argus Salud Pharma LLP. Consequently the Companys share in LLP has increased to 99.90% in Argus Salud Pharma LLP.In October 2016, the Company had subdivided the shares from the face value of Rs 10/ to Rs 2/ and upon subdivision, the members were issued five equity shares of Rs 2/ each in lieu of one equity share of Rs 10/ each. After subdivision, the paid up capital of Rs15,11,00,000 was sub divided into 7,55,50,000 equity shares of Rs 2/ each.As on 31 March 2018, the Company has three subsidiaries, viz Argus Salud Pharma LLP, Caplin Point Far East Limited Hongkong and Caplin Point Laboratories Colombia SAS Colombia.During the year 2019, the Company transferred its regulated markets injectable business which, interalia includes US FDA approved injectable plant and Department of Science and Industrial Research (DSIR) recognised R D Units CP4 and CP 5 to Caplin Steriles Limited, a Wholly Owned Subsidiary Company for which the approval was granted by the members of the Company by way of Special Resolution through Postal Ballot on December 31, 2018.In FY2019, the Company attracted investments in Caplin Steriles Limited from Eight Roads Ventures India Ill LP and FPrime Capital Partners Life Sciences Fund VI LP in the form of Compulsorily Convertible Preference Shares (CCPS), which shall be converted into equity shares of Caplin Steriles Limited based on the agreed terms.During FY 2019, the Company formed a Joint Venture, Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Hainan Province of China, which will be focusing on international trade of medicines and establishment of marketing team in India and China for export of composite formulations to customers in China, India, Europe and Latin America.In FY21, Company acquired four channel partners in Latin America, strengthening control on marketing, distribution and supply chain. It launched an ecommerce website named QueTenX, a part of the 10X healthcare portal, transforming credit sales into cash, enhancing an analysis of demand and supply patterns and replenishment stocks through technology tools. It deepened capabilities by stocking essential products at warehouses during the COVID19 months. It commissioned a DGCIapproved CRO facility and captive API development kilo lab to facilitate backward integration. It received approvals for nine of 18 ANDAs filed (six for Caplin Steriles) five products launched the next four to be launched in the near future. It embarked on a pipeline of 15 ANDAs to be filed within 24 months with an addressable market size of USD 1.95 billion. It completed ab scale batches for 17 products for US (by Caplins API division) and trebled capacity of the manufacturing facility.The Company received four ANDA approvals since January 2021, increasing approved ANDAs to 15 (ten under Caplins name and five through partners). It launched eight products in US four products are ready for launch and three are likely to be launched before December 2021. It received large tender orders worth 18 million in two markets and has started RD for API and Oncology formulations in existing and new markets. The registrations for formulations are in progress as such. The design /detailed engineering for Phase 2 of Injectable Plant is complete. Overall Project cost is Rs. 140 Crore and will include 2 Vial lines, one Lyophilizer line, one Pre filled syringe line and provision to add another Premix bag line.During the year 202223, the Company had disposed its entire investment in Caplin Point Laboratories Colombia SAS to Caplin Point Far East Limited Hong Kong, a wholly owned subsidiary of the Company and effective from March 28, 2023, Caplin Point Laboratories Colombia SAS ceased to be a subsidiary but became a stepdown subsidiary.In 2023, Caplin doubled its capacity to produce Softgel formulation at its Puducherry facility. The Company implemented the latest, S4 hana, version of SAP enterprise resource planning system. It developed new line of products i.e. Oncology. It completed 4 complex products Exhibit Batches, which includes 3 Injectables and 1 Ophthalmic launched colabelled products in the US, for 4 approved products. It launched 23 new products in Central America which has contributed to 2.4m dollars in sale. The second line of production in Softgel dosage was completed in 2023. It acquired an API plant in Visakhapatnam, Andhra Pradesh.
Read More

Caplin Point Laboratories Ltd FAQs

Caplin Point Laboratories Ltd shares are currently priced at 1521.5 on NSE and 1519.8 on BSE as of 2/21/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Caplin Point Laboratories Ltd [CAPLIPOINT] share was 126.83. The Caplin Point Laboratories Ltd [CAPLIPOINT] share hit a 1-year low of Rs. 575 and a 1-year high of Rs. 1619.05.

The market cap of Caplin Point Laboratories Ltd is Rs. 11554.54 Cr. as of 2/21/2024 12:00:00 AM.

The PE ratios of Caplin Point Laboratories Ltd is 43.04 as of 2/21/2024 12:00:00 AM.

The PB ratios of Caplin Point Laboratories Ltd is 9.11 as of 2/21/2024 12:00:00 AM

The Mutual Fund Shareholding was 0.41% at the end of 2/21/2024 12:00:00 AM.

You can easily buy Caplin Point Laboratories Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage